Vaxcyte shares rise 1.90% after-hours as VAX-31 Phase 2 study advances to final stage.

Vaxcyte, Inc. rose 1.90% in after-hours trading, driven by positive news regarding the advancement of its VAX-31 infant Phase 2 dose-finding study. The company announced that the study has progressed to its final stage, evaluating the safety, tolerability, and immunogenicity of VAX-31 compared to Prevnar 20. Additionally, Vaxcyte reported that the optimized dose of VAX-31 is designed to elicit stronger immune responses in infants, potentially offering broader coverage against invasive pneumococcal disease.